Editorial

You have full text access to this OnlineOpen article

Exploiting T cell crosstalk as a vaccination strategy for rheumatoid arthritis

  1. Berent Prakken1,*,
  2. Salvatore Albani2

Article first published online: 30 JAN 2007

DOI: 10.1002/art.22317

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 56, Issue 2, pages 389–392, February 2007

Additional Information

How to Cite

Prakken, B. and Albani, S. (2007), Exploiting T cell crosstalk as a vaccination strategy for rheumatoid arthritis. Arthritis & Rheumatism, 56: 389–392. doi: 10.1002/art.22317

Author Information

  1. 1

    University Medical Center Utrecht, and Wilhelmina Children's Hospital, Utrecht, The Netherlands, and EUREKA Institute for Translational Medicine, Syracuse, Italy

  2. 2

    EUREKA Institute for Translational Medicine, Syracuse, Italy, University of California, San Diego, and Androclus Therapeutics, San Diego, California

*Department of Pediatric Immunology KC.03.063.0, University Medical Center Utrecht, PO Box 85090, 3508 GA Utrecht, The Netherlands

Publication History

  1. Issue published online: 30 JAN 2007
  2. Article first published online: 30 JAN 2007
  3. Manuscript Accepted: 29 SEP 2006
  4. Manuscript Received: 10 AUG 2006

Funded by

  • Fifth Framework Program “HSP for therapy,”
  • Dutch Arthritis Foundation
  • Dutch Organization for Scientific Research
  • NIH. Grant Numbers: 5P50-AR-44850-04, N01-AR-9-2241, 2R01-AI-41721-05, 1R01-AR-48084-01

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (51K)

REFERENCES

  • 1
    Firestein GS. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J Clin Invest 2004; 114: 471–4.
  • 2
    Goronzy JJ, Weyand CM. T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol 2004; 16: 212–7.
  • 3
    Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004; 200: 277–85.
  • 4
    Albani S, Prakken B. T cell epitope–specific immune therapy for rheumatic diseases [review]. Arthritis Rheum 2006; 54: 19–25.
    Direct Link:
  • 5
    De Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H, Klein M, et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004; 172: 6435–43.
  • 6
    Broeren CP, Lucassen MA, van Stipdonk MJ, van der Zee R, Boog CJ, Kusters JG, et al. CDR1 T-cell receptor β-chain peptide induces major histocompatibility complex class II-restricted T-T cell interactions. Proc Natl Acad Sci U S A 1994; 91: 5997–6001.
  • 7
    Lohse AW, Mor F, Karin N, Cohen IR. Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells. Science 1989; 244: 820–2.
  • 8
    Honda A, Ametani A, Matsumoto T, Iwaya A, Kano H, Hachimura S, et al. Vaccination with an immunodominant peptide of bovine type II collagen induces an anti-TCR response, and modulates the onset and severity of collagen-induced arthritis. Int Immunol 2004; 16: 737–45.
  • 9
    Mimran A, Mor F, Carmi P, Quintana FJ, Rotter V, Cohen IR. DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response. J Clin Invest 2004; 113: 924–32.
  • 10
    Cohen IR, Quintana FJ, Mimran A. Tregs in T cell vaccination: exploring the regulation of regulation. J Clin Invest 2004; 114: 1227–32.
  • 11
    Chen G, Li N, Zang YC, Zhang D, He D, Feng G, et al. Vaccination with selected synovial T cells in rheumatoid arthritis. Arthritis Rheum 2007; 56: 453–63.
    Direct Link:
  • 12
    Vandenbark AA. TCR peptide vaccination in multiple sclerosis: boosting a deficient natural regulatory network that may involve TCR-specific CD4+CD25+ Treg cells. Curr Drug Targets Inflamm Allergy 2005; 4: 217–29.
  • 13
    Panoutsakopoulou V, Huster KM, McCarty N, Feinberg E, Wang R, Wucherpfennig KW, et al. Suppression of autoimmune disease after vaccination with autoreactive T cells that express Qa-1 peptide complexes. J Clin Invest 2004; 113: 1218–24.
  • 14
    Moreland LW, Morgan EE, Adamson TC III, Fronek Z, Calabrese LH, Cash JM, et al. T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vβ3, Vβ14, and Vβ17 peptides. Arthritis Rheum 1998; 41: 1919–29.
    Direct Link:
  • 15
    Kotzin BL, Kappler J. Targeting the T cell receptor in rheumatoid arthritis [editorial]. Arthritis Rheum 1998; 41: 1906–10.
    Direct Link:
  • 16
    Van Laar JM, Miltenburg AM, Verdonk MJ, Leow A, Elferink BG, Daha MR, et al. Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis. J Autoimmun 1993; 6: 159–67.
View Full Article (HTML) Get PDF (51K)